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Abstract
Background: Glutaric aciduria type I (GA-I) is an inherited metabolic disease due to deficiency of glutaryl-CoA
dehydrogenase (GCDH). Cognitive functions are generally thought to be spared, but have not yet been studied in
detail.
Methods: Thirty patients detected by newborn screening (n = 13), high-risk screening (n = 3) or targeted metabolic
testing (n = 14) were studied for simple reaction time (SRT), continuous performance (CP), visual working memory
(VWM), visual-motor coordination (Tracking) and visual search (VS). Dystonia (n = 13 patients) was categorized using
the Barry-Albright-Dystonia Scale (BADS). Patients were compared with 196 healthy controls. Developmental
functions of cognitive performances were analysed using a negative exponential function model.
Results: BADS scores correlated with speed tests but not with tests measuring stability or higher cognitive
functions without time constraints. Developmental functions of GA-I patients significantly differed from controls for
SRT and VS but not for VWM and showed obvious trends for CP and Tracking. Dystonic patients were slower in SRT
and CP but reached their asymptote of performance similar to asymptomatic patients and controls in all tests.
Asymptomatic patients did not differ from controls, except showing significantly better results in Tracking and a
trend for slower reactions in visual search. Data across all age groups of patients and controls fitted well to a model
of negative exponential development.
Conclusions: Dystonic patients predominantly showed motor speed impairment, whereas performance improved
with higher cognitive load. Patients without motor symptoms did not differ from controls. Developmental functions
of cognitive performances were similar in patients and controls. Performance in tests with higher cognitive demand
might be preserved in GA-I, even in patients with striatal degeneration.
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Background
Glutaric aciduria type I (GA-I) is caused by autosomal
recessive mutations in the GCDH gene (cytogenetic
location: 19p13.2) resulting in glutaryl-CoA dehydrogen-
ase (GCDH; EC 1.3.99.7) deficiency) [1] and elevated
concentrations of glutaryl-CoA, glutaric acid (GA), 3-
hydroxyglutaric acid (3-OH-GA) and glutarylcarnitine
(C5DC) in body tissues. GA and 3-OH-GA are considered
to be neurotoxic [2–5]. Two biochemical subtypes, excret-
ing low vs. high concentrations of GA and 3-OH-GA
in urine have been delineated [6]. Cerebral accumula-
tion of GA and 3-OH-GA is induced by cerebral de
novo synthesis and low efflux transport of these metabo-
lites across the blood–brain barrier [7–9].
Delayed brain maturation starting in the last trimester
of pregnancy results in temporal hypoplasia, immature
gyral patterns and delayed myelination [10–13]. The
prognostic relevant clinical presentation is a predomin-
antly dystonic movement disorder due to striatal injury
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which may manifest insidiously or acutely after a preced-
ing acute encephalopathic crisis [11, 14, 15], usually
within the first three years of life. Early diagnosis and
start of metabolic treatment comprising low lysine diet,
carnitine supplementation and emergency treatment
during episodes that are likely to induce catabolism like
febrile illness can prevent striatal injury and improve
neurological outcome [15–20].
Whereas susceptibility to striatal injury is restricted to
a vulnerable period in infancy and early childhood,
extrastriatal MRI changes such as T2 hyperintensity
of supratentorial white matter may increase with age
[11, 21]. These changes correspond to spongiform
myelinopathy due to myelin splitting and intramyelinic
vacuolation as shown by post mortem studies [22–24].
Severe white matter changes are the characteristic finding
in GA-I patients with a late-onset disease variant.
However, white matter changes may already start during
childhood – even in patients identified by newborn
screening [11, 25, 26].
Neuropsychological function comprises several steps of
information processing from encoding of stimuli, working
memory, decision making, attention and organization of
motor function. These steps require structural and func-
tional integrity of specific gray and white matter, and
circuits including cortex, basal ganglia and thalamus, i.e.
cortico-striato-thalamocortical loop [27]. Given the char-
acteristic cerebral abnormalities in GA-I and in analogy to
white matter changes in other neurological diseases [28],
patients might be at risk for neurobehavioral impairment
of reaction times, information processing or abnormal
development of cognitive functions. Basal ganglia injury,
frontotemporal cortical hypoplasia and accumulating neu-
rotoxins might further increase this risk [11, 27, 29–31].
Most studies on GA-I were performed in paediatric
patients and focussed on motor dysfunction. The general
assumption is that intellect is spared in GA-I [32]. In
fact, normal cognitive function was reported, however,
studies had only small sample sizes and no control group
[33]. However, decreased IQ or more subtle cognitive
deficits were also reported for a few children with GA-I
[34, 35] and cognitive decline was found in late-onset GA-
I patients [26], The few studies on cognitive function in
GA-I only focussed on IQ but not on development of
cognitive function. Given the ubiquitous results that even
well-treated patients with GA-I show frequent neurora-
diological abnormalities [11, 36] the present study investi-
gates a broader spectrum of neuropsychological functions
from childhood to adulthood.
The aims of the present study were (1) to analyse the
development of neuropsychological functions in symp-
tomatic as well as asymptomatic GA-I patients focussing
on information processing measuring simple reaction
time, continuous performance, visual working memory,
visual motor coordination and visual search using a
computer-based test battery and to compare the results
with age-matched healthy control group data, and (2) as-
sessment of the impact of dystonic movement disorder
on test results.
Methods
Study samples
We investigated 30 patients (12 female and 18 male)
with confirmed diagnosis of GA-I who are followed by
our own department or are members of the German
GA-I patient group (http://www.glutarazidurie.de). Only
patients of at least 5 years of age were included in the
study (age range 5–29 years) due to our clinical experi-
ence that younger children usually are not able to
perform all subtests of our battery or to cope with a total
test time of 60 minutes. Patients with dystonia in their
hands unable to manage the response panel of our test
battery did not participate. Patients’ data were compared
with those of healthy subjects (n = 196; age range 5–28
years, 93 female and 103 male). Control group data for
children and adolescents have been collected in local
schools and for adults at workplaces requiring different
educational levels before this study for evaluation of
other metabolic diseases, e.g. phenylketonuria. Detailed
information on age group sizes of patients and controls
are given in Additional file 1: Table S1.
The study was approved by the Institutional Ethics
Committee of the Medical Faculty of Heidelberg University
(No. 314/2002; S-49/2010; S-525/2010). Data were col-
lected after written informed consent had been obtained
from GA-I patients or their parents as well as control sub-
jects and were pseudonymized before statistical analysis.
Outcome parameters
Dystonia
Severity of dystonia was determined using the Barry-
Albright Dystonia Scale (BADS, [37]). The BADS is a five-
point ordinal scale (0 = no dystonia; 1 = slight; 2 = mild;
3 = moderate; 4 = severe) quantifying dystonia in eight
body regions (eyes, mouth, neck, trunk, right and left
upper and lower extremities), by a score ranging from 0
to 32. Accordingly, subjects without motor symptoms
received a BADS score of zero.
Reaction times and information processing
The computer-based neuropsychological test battery
used for this study was compiled by two of the authors
(PB, SG) for testing patients with inherited metabolic
diseases [38, 39]. The aim of the battery is to test basic
processes of information processing mostly devoid of
educational influences using the same tasks across the
age range from childhood to adulthood. The five
subtests measure different basic aspects of information
Boy et al. Orphanet Journal of Rare Diseases  (2015) 10:163 Page 2 of 12
processing using standard neuropsychological paradigms
[40, 41]. The test battery comprises pure motor speed
tests (simple visual reaction time, visual motor coordin-
ation), speed tests with low (continuous performance) or
increasing (visual search 1,2,3) cognitive demand, and a
test without time constraints and high cognitive demand
(visual working memory). The tracking and the continu-
ous performance tests measure level of performance as
well as stability of performance over time. Five tests
were administered individually to each patient.
In the simple reaction time (SRT) task a sequence of
80 black squares appears on the screen and requires
pushing a button as fast as possible. Inter-stimulus inter-
vals are randomized to prevent strategy effects. Test
scores are calculated as the mean of 80 reactions (40 with
the dominant and 40 with the non-dominant hand).
Visual-motor coordination (Tracking) was measured with
a smiley moving on the computer screen which has to be
pursued with the mouse cursor as close as possible. To in-
crease difficulty mouse cursor movements are attenuated,
i.e. slightly delayed in time. Test scores are mean distance
between the cursor and the smiley for speed and SD of
the distance for stability of performance. Continuous per-
formance (CP) was measured in a choice reaction time
paradigm. A sequence of 600 patterns of three, four or five
squares is presented. A button for the dominant hand has
to be pushed after four squares (hits) and a button for the
non-dominant hand after three or five squares. Test scores
are mean reaction time for hits measuring level of
performance and standard deviation of single hit times
measuring stability of performance. In Visual search (VS)
the time to decide whether or not a squared pattern of
four different letters contained a set of target letters was
measured. Tested are three loads of one (VS1), two (VS2)
or three target letters (VS3). Test scores were mean
reaction times for correct choices in the three loads. In
the visual working memory (VWM) task a target checker
board pattern of 64 black or white squares is presented for
one second. After an inter-stimulus interval the target is
presented together with three distractors (same size
checker boards with different patterns). The subject has to
decide which of the options shows the target stimulus,
and to choose it by a mouse click. There is no time limit
for decision making. The first ten trials are used to adap-
tively define a subject’s baseline performance of discrimin-
ation, where the target-distractor similarity is stepwise
increased or decreased according to the subject’s perform-
ance. In the following ten trials the subject’s test perform-
ance is determined by the mean number of different fields
for correct differentiations between target and distractors
(mean contrast).
Statistical analysis
Raw scores for all psychological tests were converted to
standard deviation scores (SDS) based on means and
standard deviations of age-matched healthy control
groups, higher SDS indicating better performance. The
age range (5–29 years) was discretized into five age
groups of two years each for ages 5 to 14 years, and five
age groups of three years each for ages 15 to 29 years.
Data of all psychological tests were log-transformed
because of non-normal distributions of raw scores.
Parameters of a mathematical model of developmental
[42, 43] (Fig. 1) were calculated for the cross-sectional
results of GA-I patients and controls separately. The
model describes developmental change by a negative
exponential function of performance Y by age (a) as
Y = b + ce-da. Parameter b represents the asymptote to
which performance converges over time, c is the differ-
ence between the maximum of Y and the asymptote and d
Fig 1 A general negative exponential model of development. The model [42, 43] describes development of performance (Y) as an exponential
function of age (a). b represents the asymptote to which the performance converges, c is the difference between maximum of Y and asymptote.
d indicates how quickly performance changes from maximum to asymptote
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indicates how fast Y changes from maximum to the
asymptote. For curve fitting of the model to the data non-
linear regression was used [44, 45]. Akaike weights were
used as criterion for global optimisation of the model pa-
rameters b, c, and d. The Akaike Information Criterion
corrected for bias (AICc) is recommended to measure
goodness of fit in non-linear modelling [46]. Unfortu-
nately, AICc is not standardized like R2, but can only be
interpreted as relative measure, with low values indicating
good and high values indicating poor fit. We therefore also
report residual sums-of-squares (RSS) indicating better vs.
poorer goodness of fit. As AICc depends on sample size,
values for the control group are in a different numerical
range than those of the patient group and subgroups.
Since the three cognitive loads of the VS task (VS1-VS3)
cannot be simultaneously handled in a single developmen-
tal model, data have been analysed as follows. Repeated
ANOVA of VS1-VS3 by group and age group revealed
significant effects for group [F(1,187) = 13.24, p < 0.001],
with patients being slower than controls, age group
[F(2,187) = 62.36, p < 0.001], with older subject being
faster (a common developmental trend), and load
[F(1.6,303.3) = 183.27, p < 0.001, Greenhouse-Geiser], with
more letters (higher cognitive demand) leading to longer
response times (a normal effect). The interaction of load
by age group was significant [F(3.2,303.3) = 7.14, p < 0.001,
Greenhouse-Geiser]. Compared with younger subjects
older ones needed less additional time from VS1 to VS2
to VS3, what can be expected, and is compatible with a
shift from serial to parallel information processing.
The interactions of load by group [F(1.6,303.3) = 0.55,
p = 0.543, Greenhouse-Geiser] and load by group by age
group [F(3.2,303.3) = 0.20, p = 0.908, Greenhouse-Geiser]
were not significant. Thus, increase of reaction time
from VS1 to VS3 and decrease of reaction time with age
are comparable in both groups. The non-significant
interaction of load by group indicates that differences
between patients and controls are the same across all
three loads. Therefore, each load can be regarded as
representing the group effect. We selected VS3 for deriv-
ing a developmental function for visual search.
Mathematical models resulting for patients and controls
were compared by the F-Test described by Mead and
Curnow [47]. Due to the explorative nature of the analysis
no adjustment of alpha-error was performed. P values ≤
0.05 were considered statistically significant, values > 0.05
and ≤ 0.1 are reported as trends.
Results
Study sample
Fourteen of the 30 GA-I patients were diagnosed by new-
born screening (median age at diagnosis 0.25 months,
range 7–17 days), 12 patients were diagnosed by targeted
metabolic studies after manifestation of a movement
disorder (median age at diagnosis 37 months, range 2–111
months), and three patients were diagnosed by high-risk
screening of families with previously diagnosed index
patients (one patient at the age of 1 month, one patient at
the age of 53 months; the exact date of diagnosis of one
patient being unknown). An additional patient was diag-
nosed coincidentally at the age of 25 years participating in
a diagnostic study. Eight patients, four asymptomatic
(24 %) and four symptomatic (31 %) did not complete all
five subtests. This difference was not significant [χ2(df = 1,
n = 30) = 0.20, p = 0.485]. Numbers and reasons of unfin-
ished tests for each subtest were for VS: n = 3 asymptom-
atic patients: lack of concentration n = 1, young child
without familiarity with letters n = 1, unknown n = 1; n = 4
symptomatic patients: young child without familiarity with
letters n = 1, fatigue with increasing dystonia: n = 1,
unknown: n = 2; for VWM: n = 1 asymptomatic patient:
lack of concentration; n = 2 symptomatic patients, both
unknown; for CP: n = 1 asymptomatic patient: fatigue after
MRI and sedation the day before; n = 1 symptomatic pa-
tient: fatigue with increasing dystonia. SRT and Tracking
subtests were finished by all patients.
Thirteen patients (43 %) had a dystonic movement
disorder, eight of them classified as mild (BADS score =
1-7), two as moderate (BADS score = 8-14) and three as
severe dystonia (BADS score > 14). In all dystonic pa-
tients, both upper extremities were involved. Seventeen
patients (57 %) were asymptomatic (BADS score = 0).
Effects of dystonia on test results
To elucidate impact of dystonia on motor reaction times,
we correlated BADS scores with neuropsychological test
results. BADS scores were unavailable for three patients
with dystonia due to missing documentation. Since BADS
scores for upper extremities significantly correlated with
total BADS scores (r = 0.918; p < 0.001, n = 27), only the
latter were used for further statistical analysis. We found a
monotonically decreasing function of performance in psy-
chological tests starting with BADS scores equal three.
Correlations were significant between BADS scores and
speed tests with low cognitive and high motor demand
(means of SRTand CP, mean and SD of Tracking; Table 1).
The speed test with high cognitive demand (VS1 VS2,
VS3), the test with high cognitive demand without time
constraints (VWM) and the stability of the test with low
cognitive demand (SD of CP) were not correlated with
BADS scores. The difference between the results of the
two stability variables for Tracking and CP will be elabo-
rated in the discussion. Partial correlations controlling for
age did not change the pattern of associations.
Developmental functions for psychological data
Table 2 reports residual sums-of-squares (RSS) indicating
better vs. poorer goodness of fit. As AICc depends on
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sample size, values for the control group are in a different
numerical range than those of the patient group and sub-
groups. There were good fits of the exponential model to
the data for all psychological test scores, both for patients
and controls, except for VWM where AICc and RSS
values were largest for patients and controls. This was in
accordance with our expectation as the developmental
model is not designed for variables without time con-
straints [42, 43].
Comparison of developmental functions Y = b + ce-da
of patients vs. controls (Fig. 2a-d) using the F-test [47]
yielded significant differences for SRT (p = 0.019) and
VS3 (p = 0.035), and trends for CP (p = 0.056) and
Tracking (p = 0.052). No significant difference was found
for VWM (p = 0.133) (Table 2). Furthermore, we com-
pared developmental functions for asymptomatic and
dystonic patients with those of controls and against each
other (Fig. 3a-d). In SRT, dystonic patients showed longer
reaction times than controls (p = 0.004). Differences
between dystonic and asymptomatic patients (p = 0.824)
as well as between asymptomatic patients and controls
were not significant (p = 0.595) (Table 2). For CP, a similar
pattern was found with only dystonic patients being sig-
nificantly slower than controls (p = 0.003) whereas asymp-
tomatic patients did not differ from controls. In the
Tracking task, dystonic patients were not significantly dif-
ferent from asymptomatic ones (p = 0.351) or controls (p
= 0.969), and asymptomatic patients showed significantly
faster reaction times than controls (p = 0.015). VS3 which
was selected for deriving a developmental function for vis-
ual search resulted in a good fit for patients as well as for
healthy control subjects. We observed a trend for asymp-
tomatic patients showing slower reaction times than con-
trols (p = 0.077). The dystonic subgroup was too small to
achieve an acceptable fit for the exponential model
(Fig. 3d). Developmental functions for VWM, a pure
cognitive demand test without time constraints, showed
highest AICc and RSS values and poor fits for GA-I
patients and controls. No developmental functions were
derived for the two stability variables, as no specific hy-
pothesis was formulated for change of variability with age.
To test whether the exponential functions of the three
groups show different gradients (Fig. 1, parameter d, i.e.
how fast the asymptotic performance is achieved), patient
and control data were aggregated into three different age
groups: a starting period (5–8 years) with a relatively low
level of performance, followed by a period of rapid im-
provement (9–12 years), and a period of relatively stable
performance without further improvement (13–29 years).
A significant interaction of group by age would indicate
different gradients. No significant interactions could be
found for SRT, CP, Tracking, VS3, or VWM (Table 3).
Discussion
This is the first study analysing different aspects of infor-
mation processing in a larger group of GA-I patients.
We have found five major results: (1) Dystonia corre-
lated significantly with motor speed. (2) In contrast,
performances with higher cognitive load (visual working
memory and visual search) as well as stability of per-
formance over time were not associated with dystonia.
(3) Developmental functions of GA-I patients were
different from those of healthy controls for motor speed
and visual search but not for visual working memory (a
test with higher cognitive demand without speed con-
straints). Dystonic patients showed significantly longer
reaction times compared to controls in simple motor
speed and continuous performance but were not differ-
ent in visual motor coordination and visual search. (4)
Overall, developmental functions of speed tests of all
three groups fitted well with the negative exponential
model. Differences between groups were mainly due to
level but not to gradient, i.e. dystonic patients were
slower from the start. The interaction of group by age
group (Table 3) was non-significant for all tests, indicating
that dystonic patients reached their asymptote of perform-
ance as fast as asymptomatic patients and controls, i.e.
although the three groups do not develop on the same
Table 1 Pearson correlation coefficients between neuropsychological tests and BADS scores
Test Construct Variable Correlation
Pearson r p n
Tracking Speed (motor demand) SDS Mean −0.720 <0.001 27
Tracking Stability (motor demand) SDS SD −0.722 <0.001 27
SRT Speed (motor demand) SDS Mean −0.505 0.007 27
CP Speed (low cognitive demand) SDS Mean −0.467 0.021 24
CP Stability (low cognitive demand) SDS SD −0.096 0.654 24
VS 1 Speed (high cognitive demand) SDS Mean L1 −0.255 0.264 21
VS 2 Speed (high cognitive demand) SDS Mean L2 −0.346 0.135 20
VS 3 Speed (high cognitive demand) SDS Mean L3 0.059 0.811 19
VWM High cognitive demand (without time constraint) SDS Mean Contrast −0.062 0.775 24
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Table 2 Parameter estimates of the exponential model with F-test for comparison of groups
Test Variable Model
parameter
Parameter
estimate (PE)
SE of PE t-test for
PE
p value
of t-test
RSS AICc PE SE of PE t-test
for PE
P value
of t-test
RSS AICc F (df1, df2) p F (df1, df2) p
n GA-I patients n Controls Pat vs. Controls Asymp. vs. Controls
SRT Log Mean b 30 2.38 0.07 33.95 <0.001 0.362 −38 196 2.38 0.01 309.48 <0.001 1.014 −467 3.40 (3,220) 0.019 −0.63 (3,207) 0.595
c 30 0.58 0.11 5.33 <0.001 196 0.92 0.13 7.05 <0.001
d 30 −0.46 0.24 −1.8 0.071 196 −0.92 0.11 −8.15 <0.001
CP Log Mean b 27 0.88 0.05 16.81 <0.001 0.508 −22 183 0.75 0.03 25.37 <0.001 1.231 −388 2.57 (3,204) 0.056 0.54 (3,193) 0.657
c 27 1.01 0.44 2.32 0.030 183 0.62 0.04 16.41 <0.001
d 27 −0.91 0.45 −2.00 0.057 183 −0.31 0.05 −5.91 <0.001
Track-ing Log Mean b 30 1.40 0.05 29.61 <0.001 0.444 −32 119 1.38 0.02 81.71 <0.001 1.458 −178 2.63 (3,143) 0.052 3.64 (3,130) 0.015
c 30 0.62 0.30 2.07 0.049 119 0.87 0.15 5.88 <0.001
d 30 −0.80 0.52 −1.53 0.137 119 −0.72 0.14 −5.26 <0.001
VS 3 Log Mean L3 b 21 3.01 0.07 46.22 <0.001 0.596 −6 172 2.88 0.03 107.14 <0.001 2.362 −241 2.93 (3,187) 0.035 2.32 (3,179) 0.077
c 21 1.63 0.69 2.37 0.029 172 0.97 0.12 8.20 <0.001
d 21 −0.90 0.39 −2.31 0.033 172 −0.46 0.08 −5.92 <0.001
VWM Log Mean Contrast b 27 0.69 0.17 4.10 <0.001 1.603 9 125 0.66 0.03 24.80 <0.001 5.923 −18 1.90 (3,146) 0.133 0.61 (3,135) 0.609
c 27 0.73 0.25 2.89 0.008 125 1.62 0.64 2.53 0.013
d 27 −0.43 0.42 −1.03 0.314 125 −1.13 0.35 −3.27 0.001
Dystonic (Dys.) patients Asymptomatic (Asymp.) patients Dys. vs. Asymp. Dys. vs. Controls
SRT Log Mean b 13 2.43 0.06 39.30 <0.001 0.131 −12 17 2.36 0.08 30.36 <0.001 0.218 −16 0.30 (3,24) 0.824 4.67 (3,203) 0.004
c 13 0.90 0.38 2.39 <0.038 17 0.80 0.27 3.01 0.009
d 13 −0.75 0.43 −1.75 0.112 17 −0.65 0.39 −1.65 0.122
CP Log Mean b 11 0.85 0.05 17.21 <0.001 0.076 −12 16 0.84 0.15 5.61 <0.001 0.382 −4 0.75 (3,21) 0.533 4.85 (3,188) 0.003
c 11 1.39 0.50 2.76 0.025 16 0.59 0.22 2.68 0.019
d 11 −0.95 0.37 −2.59 0.032 16 −0.46 0.50 −0.92 0.377
Track-ing Log Mean b 13 1.41 0.06 21.81 <0.001 0.158 −10 17 1.29 0.09 15.01 <0.001 0.231 −15 1.14 (3,24) 0.351 0.08 (3,126) 0.969
c 13 1.00 0.47 2.15 0.057 17 0.70 0.24 2.92 0.011
d 13 −0.80 0.47 −1.69 0.123 17 −0.60 0.42 −1.43 0.175
VS 3 Log Mean L3 b 8 2.50 10.02 0.25 0.813 0.192 7 13 3.00 0.09 31.97 <0.001 0.356 1 n.d. n.d. n.d. n.d.
c 8 0.78 9.59 0.08 0.939 13 1.72 0.82 2.10 0.062
d 8 −0.06 0.97 −0.06 0.956 13 −0.90 0.47 −1.91 0.085
VWM Mean Contrast b 11 0.64 0.34 1.88 0.100 0.652 12 16 0.79 0.10 8.10 <0.001 0.845 8 0.49 (3,21) 0.690 2.09 (3,130) 0.105
c 11 0.91 0.50 1.80 0.110 16 6.35 47.34 0.13 0.895
d 11 −0.36 0.53 −0.69 0.513 16 −2.81 7.57 −0.37 0.717
F-test according to Mead and Cournow 1983. Data of all psychological test scores show good fits to the model (R2adj ≥ 0.442), both for GA-I patients (n = 30; asymptomatic: n = 17; dystonic: n = 13) and controls (n = 196),
with the exception of VS3 for dystonic patients. For definition of model parameters b,c and d see Fig. 1. R2adj: adjusted explanatory power of the regression model. SE: standard error
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level, the form of their development is the same (in analogy
to growth development on different percentiles). (5) Per-
formance of asymptomatic patients did not significantly dif-
fer from controls, except for visual motor coordination,
where asymptomatic patients showed significantly better
results, and visual search, where asymptomatic patients
showed a trend for slower reaction times.
Effects of dystonia on test results
The differential association between BADS scores and
information processing is a strong argument for the
internal validity of our test battery. Speed tests are sus-
ceptible for motor impairment whereas tests with higher
cognitive demand without time constraints are not. The
difference in the results of the two stability measures
can be explained by specific facets of the tasks. Stability
in Tracking is measured by the distance of the mouse
pointer from the moving smiley, i.e. high stability is
achieved by continuous adaptation of the direction of the
mouse pointer to the randomly changing direction of the
smiley. In contrast, stability in continuous performance
(CP) is measured by variation of reaction times in a repeti-
tive motor task. Overall slower and faster subjects can
have the same stability, e.g. by remaining on their relative
speed level during the whole test. Dystonic patients also
showed longer reaction times in motor speed (SRT) and
CP due to their motor handicap. Notably, in visual working
memory (VWM), a test without time constraints, dystonic
patients did not differ from asymptomatic patients and
controls. These results show (1) that it is possible and
necessary to separate speed (motor) and non-speed infor-
mation processing, and (2) that cognitive functions might
be preserved even in symptomatic GA-I patients.
Development of neuropsychological functioning in
GA-I patients
In analogy to growth development described by anthropo-
metric parameters on growth charts, age related changes
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Fig. 2 a–d. Developmental functions for SRT (a), CP (b), Tracking (c) and VS3 (d) of GA-I patients and controls. Patients (red) and controls showed
significant differences for SRT and VS3 and an obvious trend for CP and Tracking (for numeric details see Table 2). Height of box: interquartile
range; bottom end of box: Q1; top end of box: Q3; bold line inside of box: median; bottom/top whiskers: lowest/highest case within 1.5 times
interquartile range; circles = outliers: distance to Q1 or Q3 respectively≥ 1.5 and≤ 3 times interquartile range
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Table 3 ANOVA test variables by group (controls, asymptomatic patients, dystonic patients) and age group (5–8, 9–12, 13–29 years)
Test Variable Source Test result
SRT Log Mean Group F(2,217) = 8.07, p < 0.001
Age group F(2,217) = 58.48, p < 0.001
Interaction (group by age group) F(4,217) = 1.49, p = 0.208
CP Log Mean Group F(2,201) = 1.63, p = 0.198
Age group F(2,201) = 52.48, p < 0.001
Interaction (group by age group) F(4,201) = 1.04, p = 0.390
Tracking Log Mean Group F(2,140) = 0.71, p = 0.496
Age group F(2,140) = 22.65, p < 0.001
Interaction (group by age group) F(4,140) = 1.44, p = 0.223
VS3 Log Mean L3 Group F(2,184) = 3.62, p = 0.029
Age group F(2,184) = 15.99, p < 0.001
Interaction (group by age group) F(4,184) = 1.54, p = 0.192
VWM Log Mean Contrast Group F(2,143) = 2.60, p = 0.078
Age group F(2,143) = 13.02, p < 0.001
Interaction (group by age group) F(4,143) = 0.61, p = 0.658
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Fig. 3 a–d. Developmental functions for SRT (a), CP (b), Tracking (c) and VS3 (d) of asymptomatic and dystonic GA-I patients and controls. Dystonic
patients (red) were slower in SRT and CP. Asymptomatic patients (green) did not differ from controls (black), except significantly better results in
Tracking and a trend for slower reactions in VS3. Height of box: interquartile range; bottom end of box: Q1; top end of box: Q3; bold line inside of box:
median; bottom/top whiskers: lowest/highest case within 1.5 times interquartile range; circles = outliers: distance to Q1 or Q3 respectively≥ 1.5 and≤
3 times interquartile range. For numeric details see Table 2
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of reaction time, information processing and other cogni-
tive functions can be described as developmental func-
tions. Mean differences of level of performance may be
clinically important, however, impaired development like
developmental arrest or loss of function would result in
different developmental trajectories.
The model of negative exponential developmental
function [42, 43] fitted well with the data for both
patient groups and healthy controls. Across all domains
investigated, asymptomatic patients showed normal
development. Dystonic patients also showed a normal
gradient over time and age, however, on a slower level
for speed tests.
For all patients, VWM was not different from controls.
SRT (slower in dystonic patients) and VWM (similar
results in patients and controls) are on the extremes of
the speed vs. cognitive demand dimension of our tests
and the pattern of our results, speed being affected in
dystonic patients, and VWM performance being normal
in dystonic as well as asymptomatic patients, supports
the hypothesis that intellect might be preserved in GA-I
[32], and neurological disease manifestation may be lim-
ited to dystonic movement disorder or subtle neurological
abnormalities. In line with our findings Brown et al. [33]
recently showed that IQ scores and executive functioning
were normal in six GA-I patients diagnosed by newborn
screening. Our concept of working memory does not in-
clude the cognitive manipulation of the stored stimulus.
However, it requires the serial comparison of a stored
image with presented stimuli by segmenting the target
and the distractors into similar and dissimilar parts, going
beyond a pure short-term memory task. The requirement
of designs using more complex cognitive paradigms is
discussed in the limitations paragraph.
Recent observations also revealed subtle or global
intellectual impairment in GA-I patients identified by
newborn screening [34–36], cognitive decline in adults
with late-onset GA-I [26] and white matter changes in
MRI progressing with age [11] as a result of spongiform
myelinopathy [22–24]. Memory deficits have not been
reported for GA-I patients – except for a 66-year-old pa-
tient with late-onset disease manifestation presenting with
a progressive neurologic disease including focal seizures,
hand tremor, ataxia, and progressive dementia [26] and
another patient identified by newborn screening who was
born prematurely and owing to significant social issues
was taken into foster care [34]. In line with this, we found
similar patterns for VWM in patients and controls. Inter-
estingly, deficits in long- and short-term memory were
recently demonstrated in Gcdh-deficient mice [48].
Normal development in spite of harmful cerebral conditions
In GA-I, numerous cerebral abnormalities have been de-
scribed, inborn and acquired, structural and functional,
that may potentially disturb cognitive function. Structural
cerebral abnormalities comprise temporal hypoplasia and
white matter changes which might already start in early
childhood [11, 25, 26]. Temporal hypoplasia, cortical
immaturity and delayed myelination might already start in
the last trimester of pregnancy [10–13]. Temporal hypo-
plasia is found in the majority of asymptomatic and
dystonic patients [11] but relevance for cognitive perform-
ance has not been studied in detail.
White matter changes also are frequent in GA-I and
seem to increase with age, both in patients with high- and
low-excreting biochemical phenotypes [11]. It has been
recently demonstrated that manifestation of neuroaxonal
impairment correlates with cerebral GA concentration
and is more often found in high excretors [36]. It has
already been shown for metachromatic leukodystrophy
and maple syrup urine disease that white matter changes
can lead to neurobehavourial and emotional disturbances,
impairment of information processing, executive function
and memory [28]. However, relevance of white matter
changes in GA-I still remains to be elucidated, since MRI
changes of white matter have also been observed in
asymptomatic GA-I patients being diagnosed by newborn
screening and prospectively treated [11, 49].
It is well established that GA-I patients are at risk for
striatal degeneration with or without the onset of an
acute encephalopathic crisis. Additionally, extrastriatal
abnormalities such as pallidal hyperintensity or other
deep gray matter changes frequently occur and might
increase with age [11]. The relevance of both striatal and
extrastriatal abnormalities to cognitive functioning is not
known. Basal ganglia play an important role in neuronal
circuits coordinating several brain functions including
movements and behaviour [31], decision making [50], ex-
ecutive function, motivation and sensory and attentional
activity [27] as well as rapid combination of information
from multiple stimuli [51]. Dystonia is the consequence of
striatal degeneration in GA-I [11, 15, 49]. Given the over-
all positive results in tests without time constraints and
higher cognitive load in dystonic patients highlights that
effects of loss of basal ganglia function, frontotemporal
hypoplasia, and white matter disease on cognitive function
needs further investigation.
In addition to inborn and acquired structural cerebral
abnormalities cognitive function in GA-I might also be
affected by disease-specific pathomechanisms: accumu-
lating neurotoxins glutaric acid and 3-hydroxyglutaric
acid might chronically affect glutamatergic signalling and
thus further increase the risk for cognitive impairment
[11, 27, 29–31]. Affection of cortical circuits and networks
due to disturbed glutamatergic signalling might decrease
processing speed but also affect memory functions due to
disturbance of excitatory postsynaptical potentials (EPSP)
that play an important role in memory processes.
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Interestingly, in spite of several harmful structural and
metabolic cerebral abnormalities in GA-I patients we
have not identified clear-cut differences in non-speed
facets between asymptomatic and symptomatic patients
and controls. Since all patients have received metabolic
treatment, this positive result speaks in favour of adherence
to current guideline recommendations [52]. However, it
remains to be elucidated whether intrinsic compensatory
mechanisms help sustaining normal cognitive develop-
ment in GA-I patients. Such mechanisms could be
exploited for treatment.
Limiting factors: study design aspects
Systematic evaluation of developmental functions of
information processing, cognition, memory, and behaviour
with sufficient sample sizes is a challenge in rare metabolic
diseases like GA-I. Although our sample is quite large, we
have to admit some limiting factors.
First, our study might underestimate the effect of
severe dystonia. The sample included only three severely
dystonic patients of which even one finished all subtests
while the other two patients did not finish only one
respectively two subtests. Furthermore, the rate of un-
finished subtests was the same in asymptomatic and
symptomatic patients. A larger group of severely dys-
tonic patients will be necessary to further investigate
the hypothesis that intellect is preserved in GA-I.
Second, age groups had unequal sizes, sometimes
with few or even no patients especially in older
groups. Therefore, we cannot exclude false-negative
findings. However, data of ten age groups were fitted
successfully to the negative exponential model,
exploiting the information of the whole data set cov-
ering a long age period. Third, new test designs
should include even more complex cognitive tasks
comprising intelligence tests, avoiding the motor
component in output measurement, e.g. by using eye
movement detection. Fourth, our findings result from
a cross-sectional analysis but the silver bullet for
developmental research is the longitudinal design,
although hard to conduct. Last not least, but more
realistic, studies combining psychological variables
with (f )MRI investigations will help to understand the
impact of cerebral abnormality on the neuropsycho-
logical phenotype of GA-I.
Conclusion
In conclusion, this first evaluation of different tasks of
information processing in a larger group of GA-I
patients has demonstrated that dystonia predominantly
impairs performance in motor speed tasks but not in
tests with higher cognitive demand. Patients without
motor symptoms did not differ from controls. Develop-
mental functions of patients and controls fitted well
to a negative exponential model and were similar.
These findings suggest that cognitive function might
be preserved in GA-I, even in patients with striatal
degeneration, and favours adherence to current guide-
line recommendations.
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